Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0917816 (
mental retardation
)
15,867
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Joubert syndrome (JS) is characterized by a distinctive cerebellar structural defect, namely the << molar tooth sign >>. JS is genetically heterogeneous, involving 20 genes identified to date, which are all required for cilia biogenesis and/or function. In a consanguineous family with JS associated with optic nerve coloboma, kidney hypoplasia, and polydactyly, combined exome sequencing and mapping identified a homozygous splice-site mutation in
PDE6D
, encoding a prenyl-binding protein. We found that pde6d depletion in zebrafish leads to renal and retinal developmental anomalies and wild-type but not mutant
PDE6D
is able to rescue this phenotype. Proteomic analysis identified INPP5E, whose mutations also lead to JS or
mental retardation
, obesity, congenital retinal dystrophy, and micropenis syndromes, as novel prenyl-dependent cargo of
PDE6D
. Mutant
PDE6D
shows reduced binding to INPP5E, which fails to localize to primary cilia in patient fibroblasts and tissues. Furthermore, mutant
PDE6D
is unable to bind to GTP-bound ARL3, which acts as a cargo-release factor for
PDE6D
-bound INPP5E. Altogether, these results indicate that
PDE6D
is required for INPP5E ciliary targeting and suggest a broader role for
PDE6D
in targeting other prenylated proteins to the cilia. This study identifies
PDE6D
as a novel JS disease gene and provides the first evidence of prenyl-binding-dependent trafficking in ciliopathies.
...
PMID:A homozygous PDE6D mutation in Joubert syndrome impairs targeting of farnesylated INPP5E protein to the primary cilium. 2416 46